Word count (not including title, abstract, research in context, acknowledgment, references, tables, and figure legends): 5,077
their diagnostic classifications in 46 of 100 patients. We also report on potential bacterial DNA bloodstream translocation in 8 of 40 patients who were originally classified by physicians as noninfected and show how host response profiling can guide interpretation of metagenomic shotgun sequencing results. Finally, we present a statistical algorithm for contaminant removal from metagenomic sequencing data using Bayesian inference.
Implications of all the available evidence: Current diagnostic techniques are inadequate for rapid microbial diagnosis and optimal management of patients with suspected sepsis. Metagenomic sequencing, which offers the promise of hypothesisfree testing to discover new organisms that would have otherwise been missed, is already being introduced into clinical practice. However, interpretation of results from this powerful approach can be difficult, given that a large fraction of positive results represents reactivated viruses, chronic infections, commensal organisms, and contamination. Host response profiling can serve as an objective adjunct in interpreting ambiguous metagenomic sequencing results. As host response assays are introduced into clinical practice, we suggest that all patients undergoing metagenomic sequencing be simultaneously tested with one of these assays. For now, we urge clinicians to carefully interpret metagenomic sequencing results with the utmost regard for patient safety and antimicrobial stewardship.
INTRODUCTION
The early recognition and diagnosis of severe infection and sepsis is a significant clinical priority. Despite advances in microbial detection methods, clinicians typically rely on presumptive clinical diagnoses and empiric therapy with broad-spectrum antimicrobials, increasing the risks for adverse drug effects 1 and the development of antimicrobial resistance. Two emerging approaches, metagenomic sequencing and host response profiling, may each promote the rapid diagnosis of sepsis. Their use in a prospective fashion, and especially in combination, has not been adequately assessed and deserves careful study.
In theory, metagenomic sequencing can identify any microorganism to the species-or strain-level without the need for a prior hypothesis or reliance on cultivation, as long as there are nucleic acids of sufficient abundance and length from the organism(s) in the specimen. Case reports, validation, and interventional studies have highlighted the potential power of this approach 2-7 . Some methods incorporate microbial enrichment or human depletion steps in order to improve 'signal to noise' ratios 8, 9 . For example, viral capture sequencing for vertebrate viruses (VirCapSeq-VERT) is a metagenomic sequencing approach that enriches for all 207 viral taxa known to infect vertebrates (including humans) with sensitivity similar to the real-time polymerase chain reaction assays currently employed in clinical microbiology laboratories 10, 11 .
The mere presence of specific molecular components of an infectious agent in a patient is insufficient however to incriminate the agent as the cause of that patient's disease 12, 13 . For example, the presence of bacterial nucleic acids in a specimen of blood could be explained by contamination of the specimen with skin bacteria or their DNA during collection 14 , or even normal low-level translocation of commensal bacteria or their components into the bloodstream during states of health 15 . Viral sequences may represent latent or clinically-irrelevant viruses in circulating blood cells or their nucleic acids in plasma. Contamination of specimens with microbial nucleic acids from laboratory reagents at the time of specimen processing has been shown to critically affect results in the study of low-microbial biomass samples, such as blood 16 . Finally, false-positive and -negative results may reflect bioinformatic errors 17 and faulty reference databases 3, 18 , or other technical errors. The failure to address these same challenges in the use of other nucleic acid-based testing approaches such as multiplex pathogen PCR panels and C. difficile PCR testing has led to unnecessary antimicrobial treatments, delayed diagnoses, and/or detrimental patient outcomes [19] [20] [21] [22] . The risks of these adverse outcomes are magnified with metagenomic approaches because of their broad range and the ubiquity of microbial nucleic acids.
Assessments of host response to infection offer the possibility of revealing mechanism, inciting factors, and outcome. Although well-established in clinical practice, most traditional analytes, such as acute phase reactants, are non-specific. Host RNA transcript-based profiles can provide evidence of a clinically relevant response with specificity for all infections or broad classes of infectious agents [23] [24] [25] [26] [27] . Thus, these methods offer complementary benefits to methods that only detect microbial signals 28 .
RNA signatures that identify whether a patient is infected and the general type of infection 25, 29, 30 (e.g. bacterial or viral) may be able to provide results in a turnaround time that would allow for initial treatment guidance, since relevant host mRNAs are highly abundant and require relatively little sample preparation. These assays, however, are limited as they generally do not provide species-level information about the causative agent.
We hypothesized that metagenomic sequencing and host response profiling could reveal clinically useful information that current, routine diagnostic tests fail to provide about the potential cause of suspected sepsis, and that their use in combination could prove complementary. Langelier et al. provided the first integration of these two approaches to diagnose lower respiratory tract infections 31 . In our study, we prospectively enrolled 200 consecutive adult patients who presented to the Emergency Department with suspected sepsis, as defined by a prior sepsis definition 32 . Next, we applied three molecular approaches with specimens from these 200 adult suspected sepsis patients: 1) metagenomic shotgun next-generation sequencing (mNGS) for bacteria detection in plasma specimens; 2) VirCapSeq-VERT for DNA and RNA virus detection in plasma specimens; and 3) a previously-defined human response-based transcript signature, Integrated Antibiotics Decision Module (IADM) 25 , to classify bacterial infection, viral infection, and noninfection-based inflammation in whole blood samples. In addition, we developed an open-source gamma-Poisson mixture modelbased Bayesian method for distinguishing blood-associated sequences (signal) from reagent-associated, contaminant DNA sequences (noise) in mNGS data. Three physicians with specialty training in infectious diseases performed chart reviews on all patients in a blinded manner and then were provided results from the three diagnostic methods in a staged fashion. We report on the added value of these methods alone and together in generating clinically relevant diagnoses.
METHODS

Subject Enrollment
This study was approved by the Stanford University Administrative Panel on Attachment 1) who met the following additional criteria: 1) 2.5 mL of whole blood in a PAXgene RNA tube (collected as part of this study protocol) and at least 200 µL of plasma, were available;
2) blood samples underwent nucleic acid extractions without errors; and
3) no access restrictions for their electronic medical record We note that our patient sample banking operations began before the new sepsis-3 definition 33 was released in 2016 and relied on a prior definition 32 . Thus, our enrollment efforts did not include patients that would have otherwise been identified under the expanded sepsis-3 definition.
In addition, we collected 2.5 ml of peripheral blood in a PAXgene RNA tube from each of 10 healthy adult volunteers in the San Francisco Bay Area to serve as controls for host response profiling. Written, informed consent was obtained from each healthy volunteer prior to sampling. Inclusion criteria for these volunteers are available in the Supplementary Methods. To distinguish blood-associated DNA sequences from contaminant sequences in plasma samples, we developed a Bayesian statistical method that leverages data from negative control samples. We ran the contaminant removal algorithm separately on the three sets of samples: Set 1, Set 2, and the Pilot Set. We analyzed the Pilot Set separately, even though it behaved similarly to Set 1, because the two sets were extracted by separate technicians and sequenced using different barcode adapters several months apart. A detailed description for our contaminant removal algorithm is provided in appendix S1, and an open-source R package of this method is available at https://github.com/PratheepaJ/BARBI.
VirCapSeq-VERT
Nucleic acid was extracted from 150 μl of plasma using the NUCLISENS Each sample pool included a negative control consisting of Salmon nucleic acid that was processed alongside the human plasma samples. Raw read counts were normalized (reads per 10,000 host subtracted total reads) and a positive score assigned to specimens with a result >0.2 and for which these reads did not represent a read pileup in one position but were distributed to three or more genome regions. We did not report on viruses of the family Anelloviridae and GB viruses as they have no established clinical significance in humans 37, 38 . Additional details on VirCapSeq-VERT sequencing and bioinformatics processing are available in supplementary methods.
Host RNA transcript profiling
We tested samples from 193 patients and 10 healthy adult volunteers with a previously described 18-gene host-response assay consisting of 1) an 11-gene set to distinguish noninfection-and infection-associated SIRS, the Sepsis MetaScore (SMS) 24 ;
and 2) a 7-gene set to distinguish bacterial and viral infections, the 'bacterial-viral metascore' (BVS) 25 . The Stanford Functional Genomics Facility extracted RNA from PAXgene RNA tubes using the QIAcube system (Qiagen) according to the manufacturer's recommendations, and then performed qRT-PCR for specific human transcripts in triplicate using commercial TaqMan assays on the Biomark HD platform (Fluidigm). Samples from seven patients were not profiled because of failure of PCR amplification. SMS and bacterial-viral scores were calculated as previously described 25 .
Since this was the first use of qRT-PCR to measure target mRNAs, we needed to re-establish SMS and BVS cutoffs for the data generated in this study. First, physicians with subspecialty training in infectious diseases (not the three physicians of the main chart review) conducted a 'host response calibration chart review' to establish baseline classifications of infection status and type for the 193 patients with host response results. Each patient's medical records were reviewed by two physicians who were blinded to mNGS, VirCapSeq-VERT, and host response profiling results. SMS and BVS score cutoffs were then re-established using the results from the 'derivation cohort' of 93 patients who were adjudicated as noninfected, or as having a bacterial or viral infection by physicians with evidence from standard-of-care microbiological tests.
Cutoffs were set to incorporate 95% sensitivity for bacterial infections. With these score cutoffs, host response classifications of 'bacterial,' 'viral,' or 'noninfected' were generated for all 193 patients. In the main chart review, physicians were presented with plots of host response results incorporating score cutoffs for only the 100 patients in the 'test cohort'. The host response calibration chart review questions and results are available in supplementary methods and supplementary attachment 1, respectively.
Main Chart Review
We recruited three physicians with subspecialty training in infectious diseases, to perform a retrospective chart review on the 200 patients in a blinded manner. They were asked to make classifications on infection status and clinical relevance of mNGS and VirCapSeq-VERT results, in a staged fashion: 1) with only medical charts; 2) with the addition of mNGS and VirCapSeq-VERT results; and 3) with the further addition of host response results. The results of chart review are summarized in figure 1, and details are provided in supplementary methods, appendix S2, and appendix S3.
RESULTS
Patient population
We recruited 200 consecutive patients in the ED with suspected sepsis; applied mNGS, VirCapSeq-VERT, and host response profiling on blood specimens of each patient; and evaluated patient clinical records in two separate physician chart reviews, as depicted in figure 1.
Patient demographics are listed in table 1. The clinical syndromes at presentation were diverse and included fever without localizing findings (32% of patients), as well as syndromes involving the respiratory (21.5%) and genitourinary (9.5%) tracts, and intraabdominal sites (16.5%). While these patients were enrolled because they met SIRS criteria and were suspected at the time of presentation by triage nurses in the ED of 
Comparison of mNGS and VirCapSeq-VERT with standard-of-care microbiology
To distinguish signal from noise and remove contaminant sequences from plasma sequence data, we developed a gamma-Poisson mixture model-based Bayesian inference method. Using the 40 negative control samples, this method identified the vast majority of taxa in our dataset as contaminants ( figure S3 ).
Subsequent analyses of mNGS output were performed on contaminant-filtered data.
Bacterial sequences were identified by mNGS in plasma matching those of the species cultivated from blood collected at the same time, from the same subject in 14 of 26 patients with positive blood cultures (table 2) Epstein-Barr Virus test on 1 patient performed within 1 day of presentation (table 2, supplementary attachment 1). However, respiratory or stool samples were not tested using VirCapSeq-VERT and there were no independent molecular or culture data indicative of viremia.
To address whether organisms detected by mNGS or VirCapSeq-VERT were likely etiologic agents for the clinical presentation, our three expert physicians independently evaluated the mNGS and VirCapSeq-VERT findings in the main chart review. Of the 40 patients with organisms detected by mNGS in plasma from the day of presentation that were not identified with standard-of-care microbiological testing 
Impact of Host Response Profiling Results on Physician Classifications
To evaluate the impact of host mRNA response signatures on physician classifications of patients, we applied the previously-established Integrated Antibiotics Decision Module (IADM) 25 We then examined the impact of host response profiling results on physician diagnostic decision-making of the 100 test cohort patients who were not used in setting host response score cutoffs. In 46 patients (46%), the addition of host response profiling results led at least two of three physicians to change their classification of infection status and type (figure 5A). We also asked physicians to classify the clinical relevance of mNGS and VirCapSeq-VERT organisms first using medical charts only and then with the addition of host response results. Ten patients had at least one physician change their classification of clinical relevance of an organism revealed by mNGS or VirCapSeq-VERT upon receiving host response scores ( figure 5B ).
Possible bacterial DNA bloodstream translocation in patients originally classified as noninfected
In eight of the 50 patients originally classified by physician consensus as probably noninfected or noninfected, mNGS detected sequences in plasma from typical commensal organisms (table S5) . Physicians noted pre-existing mucosal membrane disturbances in five of these eight patients, thus raising the possibility of bacterial DNA translocation from heavily colonized mucosal sites. For example, Pt_070, who had high abundances of sequences from more than 20 oral cavity-associated organisms in plasma, had documented gingivitis and hemoptysis. All eight patients improved after their ED visit, six of whom were not prescribed antibiotics. Host response results could have been useful to physicians for interpreting ambiguous mNGS results from these patients. However, most of these patients were in the 'derivation cohort' used for setting host response cutoffs, and thus did not have their host response results assessed in the main chart review ( figure 4B ). Nonetheless, host response profiling predicted that five of the eight patients were not infected (table S5) .
Data from mNGS, VirCapSeq-VERT, host response, and physician chart reviews for all 200 patients are provided in supplementary attachment 1.
Discussion
Diagnosing infections in patients with suspected sepsis is challenging, particularly in those with multiple co-morbidities. We applied two broad-range sequencing approaches, mNGS and VirCapSeq-VERT, as well as host response profiling to a prospectively-sampled cohort of 200 adults with suspected sepsis who were enrolled in an Emergency Department. The consecutive convenience sample reflects real-world patient heterogeneity in a tertiary care hospital. We evaluated diagnostic decision-making by three infectious disease physicians as they received information from the electronic medical record, the two sequencing-based methods, and host response profiling in a staged fashion. Our results show that the sequencing methods can detect clinically relevant organisms that were missed by routine microbiological diagnostic methods, as well as other organisms that were not deemed clinically relevant. In addition, we demonstrated the potential for host response profiling to influence diagnostic decision-making and help interpret metagenomic sequencing results.
One of the most important features of unbiased, 'shotgun' metagenomic sequencing is that it is hypothesis-free, allowing simultaneous detection of thousands of organisms, including those difficult-to-culture. Seventeen of the 200 patients had clinically relevant organisms detected by mNGS and VirCapSeq-VERT that were not detected by standard-of-care microbiology within five days after presentation. Results from nine of these 17 patients led physicians to change their classifications of infection status and type. For example, patient Pt_083 presented with fever after travel to the Sierra mountains and was presumed to have a urinary tract infection by treating physicians. However, this patient was determined by mNGS to have tick-borne relapsing fever due to Borrelia hermsii. Our positivity rate was comparable to other clinical metagenomics studies as reviewed by others 39, 40 . For example, in a study of 204 meningitis and encephalitis patients diagnoses in 13 of them were made solely by metagenomic sequencing with CSF samples, with an impact on patient management in 7 of the 13 41 . In a study of cell-free plasma in 358 febrile sepsis patients, 15% of patients had probable causal pathogens detected solely by metagenomic sequencing 5 .
It should be noted that metagenomic sequencing can provide a 53-hour turnaround time 5 , which is shorter than standard-of-care tests in some situations.
Contaminant sequence identification and computational removal represents one
of the greatest barriers to expanding the clinical application of metagenomic sequencing, especially in specimens with low microbial biomass such as blood. The gamma-Poisson mixture model-based Bayesian inference approach that we have introduced here offers an important advance in addressing this challenge. In our implementation, we assumed that DNA sequences in plasma included those of contaminants. We then inferred the true 'intensity' of DNA sequences in a plasma sample that might be attributed to 'true' blood-associated nucleic acids. This method adds to others available to researchers for contaminant removal 4, 36, 37 . For example, for studies with fewer than three negative control samples, simply subtracting species based on their presence or abundance in negative controls 42 may be most appropriate.
While the decontam 43 method is not well-suited for our data because it assumes that samples have a relatively higher biomass than controls, and that each taxon is either a contaminant or 'true' but not both, it can be very helpful for 16S rRNA gene amplicon sequence data from other kinds of samples.
As metagenomic sequencing enters clinical practice, it is important to recognize the potential of this powerful approach to reveal true signals, as well as clinically- 45 , manufacture contaminant-free extraction kits, and enrich for microbial sequences 6, 8 are steps in the right direction to prepare metagenomic sequencing for routine clinical use, but much work remains to be done.
Our bacterial contaminant sequence identification method did not subtract all contaminant sequences in our mNGS dataset. Increasing the number of negative control samples in every extraction batch could aid in profiling the large diversity of contaminating taxa and thus enhance contaminant sequence removal. Furthermore, our negative control samples were only suited for identifying extraction reagent contaminants. We were not positioned to account for skin-associated contaminants or spurious sample-to-sample cross-contaminants.
The host response profiling assay classified many viral and noninfected patients as bacterial. One possible reason for these misclassifications was the strict dichotomous cutoffs that we used to distinguish infected vs. noninfected cases, and viral vs. bacterial infections. Reporting results with numeric values rather than dichotomous cutoffs will allow better weighting of these scores in patient assessments. Another reason for the misclassifications was the need to re-establish host response score cutoffs for this study's qRT-PCR platform and the small number of known viral patients with which to do so. Further work is needed to establish and lock cutoffs, validate on additional patient populations, and quantify test characteristics.
We believe that host response profiling and shotgun sequencing will soon achieve turnaround times of less than 90 minutes and 24 hours, respectively. In our chart review, physicians had access to the patients' full medical chart histories, including test results that only became available several days after presentation. If it were possible to limit the review to the first 90 minutes of each case history, we expect that there would have been greater changes in diagnostic decision-making across the stages of our chart review.
A central limitation in evaluating new diagnostic tools is the lack of a gold standard. We did our best to address this using expert physicians in a staged chart review. Fundamentally, it is impossible to determine whether the changes in patient classification were correct. However, the measurement of a diagnostic tool's ability to change clinical decision-making, rather than just a comparison of its results to standardof-care testing, is a valuable component of establishing clinical utility. An important secondary finding was that clinicians had varying levels of trust in these new diagnostic tools. In conclusion, our proof-of-concept study on a consecutive, prospectivelysampled patient cohort suggests that integrating host response profiling with metagenomic sequencing may synergistically enhance the utility of each assay, and ultimately, the diagnosis of patients with suspected sepsis. Median (Interquartile Range) 51.5 (35-68) *Information on infection status and type was collected from the main chart review while physicians were blinded to mNGS, VirCapSeq-VERT, and host response results. The 'probable or unsure' category includes all patients without a definite known diagnosis, including those classified as probable noninfected, probable bacterial, probable viral, and unsure. Classifications had consensus agreement by at least two of three physicians. Details on how each patient was placed into each category is provided in the Supplementary Methods. All other information in this table was extracted by a single physician at the completion of our study.
†Refers to the localization of signs and symptoms of patients at presentation. ‡Systemic refers to non-localized infection, sepsis, 'viral syndrome', fever with neutropenia, postoperative fever, and/or SIRS findings on presentation not related to infection, such as those associated with malignancies (e.g., leukemia, lymphoma, and metastatic tumors), and autoimmune disorders. Radiation Pneumonitis *Only organisms that were classified as 'clinically relevant' or 'probably clinically relevant' to the patient's presentation by consensus in the main chart review were included in this Table. 32 †For bacterial organisms, numbers in parentheses represent raw reads, estimated lower limit for the intensity of blood-associated reads, and estimated upper limit for the intensity of contaminant reads in ¶Indicates patients from derivation cohort who had their host response results used to re-establish cutoffs for host response scores (see Figure 4B ). CoNS = Coagulase Negative Staphylococcus, Cx = Culture, d = days bacterial, probably noninfected) or unsure diagnosis. Physicians did not evaluate host response scores from seven patients who had host response assay fail due to amplification errors, and 93 patients who had host response scores used to set cutoffs. 35 For Phase III, the same classification from Phase II was kept for patients who did not have host response scores for evaluation. Details for all patients with positive mNGS and VirCapSeq-VERT results which were not previously detected by standard-of-care microbiological testing are presented in Table   S2 and S4, respectively. †Host response assay on 7 patient samples failed due to amplification errors. ‡See Figure 4B for additional details. § Host response results from 93 patients for whom physicians classified as likely bacterial, likely viral, or likely noninfected during the host response calibration chart review were used to set score cutoffs for all patients. We did not further evaluate host response scores from these 93 patients in the main physician chart review. See Figure 4B for additional details. 
